Thibault Mésplède

3.4k total citations
108 papers, 2.7k citations indexed

About

Thibault Mésplède is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Thibault Mésplède has authored 108 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Infectious Diseases, 85 papers in Virology and 43 papers in Molecular Biology. Recurrent topics in Thibault Mésplède's work include HIV Research and Treatment (85 papers), HIV/AIDS drug development and treatment (85 papers) and Biochemical and Molecular Research (33 papers). Thibault Mésplède is often cited by papers focused on HIV Research and Treatment (85 papers), HIV/AIDS drug development and treatment (85 papers) and Biochemical and Molecular Research (33 papers). Thibault Mésplède collaborates with scholars based in Canada, United States and France. Thibault Mésplède's co-authors include Mark A. Wainberg, Peter K. Quashie, Ying-Shan Han, Maureen Oliveira, Kaitlin Anstett, Bluma Brenner, Diane N. Singhroy, Nathan Osman, Said Hassounah and Hongtao Xu and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Molecular and Cellular Biology.

In The Last Decade

Thibault Mésplède

105 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thibault Mésplède Canada 31 1.9k 1.8k 1.1k 404 348 108 2.7k
Karl Salzwedel United States 23 1.1k 0.6× 1.6k 0.9× 826 0.8× 410 1.0× 512 1.5× 27 2.4k
Wade Blair United States 26 1.1k 0.5× 1.1k 0.6× 664 0.6× 458 1.1× 430 1.2× 45 2.1k
Shuzo Matsushita Japan 29 1.2k 0.6× 1.8k 1.0× 780 0.7× 454 1.1× 1.1k 3.3× 100 2.9k
Joséphine Sire France 25 824 0.4× 1.1k 0.6× 738 0.7× 346 0.9× 460 1.3× 49 1.8k
Manos Perros United Kingdom 21 1.3k 0.7× 1.6k 0.9× 688 0.6× 383 0.9× 507 1.5× 35 2.5k
Sebla B. Kutluay United States 21 504 0.3× 899 0.5× 860 0.8× 394 1.0× 522 1.5× 31 1.7k
Christiane Moog France 30 845 0.4× 1.9k 1.1× 678 0.6× 452 1.1× 1.5k 4.2× 131 2.9k
L Rimsky United States 25 2.0k 1.0× 1.9k 1.1× 692 0.6× 462 1.1× 655 1.9× 39 3.2k
Eleftherios Michailidis United States 24 1.2k 0.6× 531 0.3× 691 0.6× 726 1.8× 252 0.7× 46 2.1k
Atsushi Koito Japan 24 574 0.3× 1.1k 0.6× 556 0.5× 294 0.7× 775 2.2× 43 1.8k

Countries citing papers authored by Thibault Mésplède

Since Specialization
Citations

This map shows the geographic impact of Thibault Mésplède's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thibault Mésplède with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thibault Mésplède more than expected).

Fields of papers citing papers by Thibault Mésplède

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thibault Mésplède. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thibault Mésplède. The network helps show where Thibault Mésplède may publish in the future.

Co-authorship network of co-authors of Thibault Mésplède

This figure shows the co-authorship network connecting the top 25 collaborators of Thibault Mésplède. A scholar is included among the top collaborators of Thibault Mésplède based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thibault Mésplède. Thibault Mésplède is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Geretti, Anna María, Marta Boffito, Stefano Bonora, et al.. (2025). Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions. Open Forum Infectious Diseases. 12(7). ofaf368–ofaf368. 2 indexed citations
2.
Ruch, Yvon, Anne Fuchs, David Rey, et al.. (2024). Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification. Clinical Infectious Diseases. 79(1). 198–201. 6 indexed citations
3.
Overmars, Ronald J., et al.. (2023). Genotypic and Phenotypic Characterization of Replication-Competent HIV-2 Isolated from Controllers and Progressors. Viruses. 15(11). 2236–2236. 1 indexed citations
4.
Oliveira, Maureen, Ruxandra-Ilinca Ibanescu, Kaitlin Anstett, et al.. (2018). Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology. 15(1). 56–56. 78 indexed citations
5.
Osman, Nathan, Thibault Mésplède, Maureen Oliveira, et al.. (2018). Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout. AIDS. 32(13). 1773–1780. 1 indexed citations
6.
Tietjen, Ian, David E. Williams, Xiaomei T. Kuang, et al.. (2018). Inhibition of NF-κB-dependent HIV-1 replication by the marine natural product bengamide A. Antiviral Research. 152. 94–103. 22 indexed citations
7.
Palanisamy, Navaneethan, Nathan Osman, Hongtao Xu, et al.. (2017). Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics study. AIDS Research and Therapy. 14(1). 2–2. 11 indexed citations
8.
Anstett, Kaitlin, et al.. (2016). Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity. Journal of Antimicrobial Chemotherapy. 71(8). 2083–2088. 37 indexed citations
9.
Han, Ying-Shan, Thibault Mésplède, & Mark A. Wainberg. (2016). Differences among HIV-1 subtypes in drug resistance against integrase inhibitors. Infection Genetics and Evolution. 46. 286–291. 38 indexed citations
10.
Hassounah, Said, Thibault Mésplède, & Mark A. Wainberg. (2016). Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review. SHILAP Revista de lepidopterología. 1(1). 41–41. 3 indexed citations
11.
Mésplède, Thibault, Peter K. Quashie, Maureen Oliveira, et al.. (2015). HIV-1 Group O Resistance Against Integrase Inhibitors. JAIDS Journal of Acquired Immune Deficiency Syndromes. 70(1). 9–15. 12 indexed citations
12.
Oliveira, Maureen, Thibault Mésplède, Daniela Moïsi, et al.. (2015). The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir. AIDS. 29(17). 2255–2260. 11 indexed citations
13.
Mésplède, Thibault, et al.. (2015). Dolutegravir inhibits HIV-1 Env evolution in primary human cells. AIDS. 29(6). 659–665. 9 indexed citations
14.
Wainberg, Mark A. & Thibault Mésplède. (2015). Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first‐line therapy. Journal of the International AIDS Society. 18(1). 20824–20824. 13 indexed citations
15.
Kramer, Victor G., Said Hassounah, Susan P. Colby-Germinario, et al.. (2014). The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. Journal of Antimicrobial Chemotherapy. 70(3). 750–756. 9 indexed citations
16.
Quashie, Peter K., Thibault Mésplède, & Mark A. Wainberg. (2012). Evolution of HIV integrase resistance mutations. Current Opinion in Infectious Diseases. 26(1). 43–49. 50 indexed citations
17.
Quashie, Peter K., Thibault Mésplède, & Mark A. Wainberg. (2012). HIV Drug Resistance and the Advent of Integrase Inhibitors. Current Infectious Disease Reports. 15(1). 85–100. 31 indexed citations
18.
Goubau, Delphine, Raphaëlle Romieu‐Mourez, Mayra Solis, et al.. (2009). Transcriptional re‐programming of primary macrophages reveals distinct apoptotic and anti‐tumoral functions of IRF‐3 and IRF‐7. European Journal of Immunology. 39(2). 527–540. 49 indexed citations
19.
Mésplède, Thibault, et al.. (2005). The POU Transcription Factor Oct-1 Represses Virus-Induced Interferon A Gene Expression. Molecular and Cellular Biology. 25(19). 8717–8731. 10 indexed citations
20.
Island, Marie‐Laure, et al.. (2002). Repression by Homeoprotein Pitx1 of Virus-Induced Interferon A Promoters Is Mediated by Physical Interaction and trans Repression of IRF3 and IRF7. Molecular and Cellular Biology. 22(20). 7120–7133. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karl Salzwedel Breakdown of academic impact, for papers by Wade Blair Breakdown of academic impact, for papers by Shuzo Matsushita Breakdown of academic impact, for papers by Joséphine Sire Breakdown of academic impact, for papers by Manos Perros Breakdown of academic impact, for papers by Sebla B. Kutluay Breakdown of academic impact, for papers by Christiane Moog Breakdown of academic impact, for papers by L Rimsky Breakdown of academic impact, for papers by Eleftherios Michailidis Breakdown of academic impact, for papers by Atsushi Koito
Rankless by CCL
2026